2021
N‐acylethanolamine‐hydrolysing acid amidase: A new potential target to treat paclitaxel‐induced neuropathy
Toma W, Caillaud M, Patel NH, Tran TH, Donvito G, Roberts J, Bagdas D, Jackson A, Lichtman A, Gewirtz DA, Makriyannis A, Malamas MS, Damaj MI. N‐acylethanolamine‐hydrolysing acid amidase: A new potential target to treat paclitaxel‐induced neuropathy. European Journal Of Pain 2021, 25: 1367-1380. PMID: 33675555, DOI: 10.1002/ejp.1758.Peer-Reviewed Original ResearchMeSH KeywordsAmidohydrolasesAnimalsEthanolaminesMicePaclitaxelPeripheral Nervous System DiseasesPPAR alphaConceptsPaclitaxel-induced peripheral neuropathyPaclitaxel-induced mechanical hypersensitivityMechanical hypersensitivitySpinal cordSelective NAAA inhibitorsNAAA inhibitorsPEA levelsDevelopment of PIPNMajor dose-limiting side effectDose-limiting side effectAdministration of palmitoylethanolamidePaclitaxel-induced neuropathyPaclitaxel-treated micePaclitaxel-induced cytotoxicityEvidence of toleranceEffective chemotherapeutic agentIntrinsic rewarding effectsLung tumor cellsNew potential targetsEndogenous palmitoylethanolamidePain aversivenessAcute administrationPeripheral neuropathyControl micePEA administrationTargeting Peroxisome Proliferator-Activated Receptor-α (PPAR- α) to reduce paclitaxel-induced peripheral neuropathy
Caillaud M, Patel NH, White A, Wood M, Contreras KM, Toma W, Alkhlaif Y, Roberts JL, Tran TH, Jackson AB, Poklis J, Gewirtz DA, Damaj MI. Targeting Peroxisome Proliferator-Activated Receptor-α (PPAR- α) to reduce paclitaxel-induced peripheral neuropathy. Brain Behavior And Immunity 2021, 93: 172-185. PMID: 33434562, PMCID: PMC8226373, DOI: 10.1016/j.bbi.2021.01.004.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsFemaleMaleMiceMice, Inbred C57BLPaclitaxelPeripheral Nervous System DiseasesPPAR alphaConceptsSensory nerve action potentialsPeripheral neuropathyCold hypersensitivityDevelopment of PNPaclitaxel-induced peripheral neuropathyPeroxisome Proliferator-Activated ReceptorsPaclitaxel-induced hypersensitivityTargeting Peroxisome ProliferatorEfficacy of fenofibrateRegulation of PPARSevere peripheral neuropathyNerve action potentialsExpression of PPARIL-6 mRNAInteresting therapeutic approachDecrease neuroinflammationCancer cell linesMechanical hypersensitivitySNAP amplitudeFenofibrate treatmentIL-1βDyslipidemia treatmentInflammatory responseTherapeutic approachesEffective treatment
2019
The α7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal
Toma W, Kyte SL, Bagdas D, Jackson A, Meade JA, Rahman F, Chen ZJ, Del Fabbro E, Cantwell L, Kulkarni A, Thakur GA, Papke RL, Bigbee JW, Gewirtz DA, Damaj MI. The α7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal. Experimental Neurology 2019, 320: 113010. PMID: 31299179, PMCID: PMC6708482, DOI: 10.1016/j.expneurol.2019.113010.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyNicotine rewardPaclitaxel treatmentRewarding effectsTreatment of CIPNPaclitaxel-induced mechanical hypersensitivityTumor-bearing NSG micePaclitaxel-induced peripheral neuropathyNon-small cell lung cancer cell linesCell lung cancer cell linesA549 non-small cell lung cancer cell lineMecamylamine-precipitated withdrawalAntitumor activityIntraepidermal nerve fibersLung cancer cell linesLung tumor growthNSCLC cell viabilityTumor-bearing miceIntrinsic rewarding effectsPlace preference testCancer cell linesConditioned place preference testMechanical hypersensitivityAgonist R